About 1 % of the world population suffers from schizophrenia. Many treatment-forms have been applied on this mental illness; drug-treatment with atypical antipsychotics being one of them. This article addresses the question if atypical antipsychotics are an effective treatment for schizophrenia. Since they take away most symptoms of schizophrenia without causing serious side-effects, they seem to be a superior treatment compared to the formerly used neuroleptics.
Table of Contents
1. INTRODUCTION
2. SCHIZOPHRENIA
3. TREATMENT WITH NEUROLEPTICS
4. TREATMENT WITH ATYPICAL ANTIPSYCHOTICS
Research Objectives and Themes
This paper investigates the therapeutic efficacy of atypical antipsychotics in the treatment of schizophrenia, specifically evaluating whether they offer a superior alternative to traditional neuroleptics by managing both positive and negative symptoms while minimizing adverse side effects. The central research question explores whether these pharmacological advancements sufficiently improve the patient's overall quality of life.
- The dopamine hypothesis of schizophrenia and its clinical implications.
- Comparative analysis of neuroleptic drugs versus atypical antipsychotics.
- Examination of side-effect profiles and their impact on patient medication compliance.
- Evaluation of subjective versus objective quality of life metrics in schizophrenic patients.
- The role of psychosocial interventions in long-term patient reintegration.
Excerpt from the Book
Effectiveness of atypical antipsychotics
The aim of any effective treatment of illness is to relieve the patient from symptoms and to restore his/her well-being. In short: to improve his/her so called health-related quality of life. This term is internationally agreed and defined as “the patient´s SELF-REPORTED health and ability to function physically, mentally and socially”. (Karow & Naber, 2001, p. 4) Next, we need to ask: Do atypical antipsychotics fulfill this criterion? Do they improve patients´ quality of life?
Voruganti and colleagues (2000) had over 600 patients, diagnosed with schizophrenia, fill out several self-administered scales concerning their subjective responses and attitudes towards their drug therapy, experienced side-effects and subjective quality of life (eg. alertness, emotional status, activities, relationships, communication and leisure activities). Patients were also assessed on a clinician administered scale for objective quality of life, taking their psychosocial functioning into account. Voruganti and colleagues found that treatment with atypical antipsychotics indeed leads to improved subjective quality of life in patients, but does NOT lead to an improvement of OBJECTIVE quality of life, measured by the clinician administered scale of psychosocial funtioning.
Summary of Chapters
INTRODUCTION: Provides an overview of the prevalence of schizophrenia and establishes the article's focus on the effectiveness of atypical antipsychotic treatments compared to traditional neuroleptics.
SCHIZOPHRENIA: Defines schizophrenia through the lens of information processing misregulation and explores the dopamine hypothesis as a basis for understanding both positive and negative symptoms.
TREATMENT WITH NEUROLEPTICS: Examines the mechanism and limitations of classical antipsychotics, highlighting high rates of extrapyramidal side effects and poor medication compliance.
TREATMENT WITH ATYPICAL ANTIPSYCHOTICS: Compares the pharmacological action of atypical agents with neuroleptics, demonstrating their enhanced ability to address negative symptoms and improve subjective patient well-being.
Keywords
Schizophrenia, atypical antipsychotics, neuroleptics, dopamine hypothesis, extrapyramidal symptoms, negative symptoms, positive symptoms, quality of life, medication compliance, psychosocial functioning, mental health, pharmacological treatment, dopamine receptors, serotonin, patient reintegration.
Frequently Asked Questions
What is the primary focus of this research paper?
The paper evaluates the effectiveness of atypical antipsychotics as a treatment for schizophrenia, specifically examining their ability to reduce symptoms while improving patient quality of life compared to older neuroleptic medications.
What are the central thematic areas discussed?
Key themes include the neurobiological basis of schizophrenia (dopamine hypothesis), the comparison between classical and atypical drug mechanisms, the impact of side effects on compliance, and the necessity of combining medication with psychosocial therapy.
What is the central research question?
The research seeks to answer whether atypical antipsychotics are an effective treatment for schizophrenia by analyzing their clinical efficacy and their impact on the patient's health-related quality of life.
Which scientific methods are utilized?
The study employs a literature-based review and statistical reanalysis of existing clinical data, such as the North American risperidone trial and studies assessing medication compliance in schizophrenic patients.
What is covered in the main body of the work?
The main body covers the definition and symptoms of schizophrenia, the mechanism and side effects of neuroleptics, the improved mechanism of atypical antipsychotics, and the critical distinction between subjective and objective quality of life.
Which keywords best define this work?
Primary keywords include schizophrenia, atypical antipsychotics, dopamine hypothesis, quality of life, and psychosocial rehabilitation.
Why do traditional neuroleptics often lead to poor treatment compliance?
Neuroleptics frequently cause severe extrapyramidal side effects, such as dystonia and tremors, and are largely ineffective at treating negative symptoms, which discourages patients from adhering to their prescribed regimen.
What is the difference between objective and subjective quality of life?
Subjective quality of life is based on the patient's self-reported feelings of well-being, whereas objective quality of life is measured by clinicians based on the patient's concrete psychosocial and functional abilities.
- Quote paper
- Elisabeth Witsch (Author), 2004, Is there a cure for schizophrenia?, Munich, GRIN Verlag, https://www.grin.com/document/27931
